Patents by Inventor Andy S. Tsai

Andy S. Tsai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic inhibitors of monocarboxylate transporters
    Patent number: 11560389
    Abstract: The invention provides compounds of formulae A, B, and C as described herein that inhibit monocarboxylate transporters, such as MCT1 and MCT4. Compounds of the invention can be used for treatment of a condition in a patient, wherein the condition is characterized by the heightened activity or by the high prevalence of MCT1 and/or MCT4, such as cancer or type II diabetes.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: January 24, 2023
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Thomas D. Bannister, William R. Roush, John L. Cleveland, Jun Yong Choi, Reji N. Nair, Andy S. Tsai, Jitendra K. Mishra
  • HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS
    Publication number: 20210094969
    Abstract: The invention provides compounds of formulae A, B, and C as described herein that inhibit monocarboxylate transporters, such as MCT1 and MCT4. Compounds of the invention can be used for treatment of a condition in a patient, wherein the condition is characterized by the heightened activity or by the high prevalence of MCT1 and/or MCT4, such as cancer or type II diabetes.
    Type: Application
    Filed: November 23, 2020
    Publication date: April 1, 2021
    Inventors: Thomas D, Bannister, William R. Roush, John L. Cleveland, Jun Yong Choi, Reji N. Nair, Andy S. Tsai, Jitendra K. Mishra
  • Heterocyclic inhibitors of monocarboxylate transporters
    Patent number: 10851113
    Abstract: The invention provides heterocyclic compounds of formula A, B, and C as described herein that inhibit monocarboxylate transporters, such as MCT1 and MCT4. Compounds of the invention can be used for treatment of a condition in a patient, wherein the condition is characterized by the heightened activity or by the high prevalence of MCT1 and/or MCT4, such as cancer or type II diabetes.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: December 1, 2020
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Thomas D. Bannister, William R. Roush, Jun Yong Choi, Reji Nair, Andy S. Tsai, Jitendra K. Mishra, John L. Cleveland
  • HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS
    Publication number: 20190330228
    Abstract: The invention provides compounds that inhibit monocarboxylate transporters, such as MCT1 and MCT4. Compounds of the invention can be used for treatment of a condition in a patient, wherein the condition is characterized by the heightened activity or by the high prevalence of MCT1 and/or MCT4, such as cancer or type II diabetes.
    Type: Application
    Filed: June 13, 2019
    Publication date: October 31, 2019
    Inventors: Thomas D. Bannister, William R. Roush, Jun Yong Choi, Reji Nair, Andy S. Tsai, Jitendra K. Mishra, John L. Cleveland
  • Heterocyclic inhibitors of monocarboxylate transporter
    Patent number: 10329303
    Abstract: The invention provides compounds that inhibit monocarboxylate transporters, such as MCT1 and MCT4. Compounds of the invention can be used for treatment of a condition in a patient, wherein the condition is characterized by the heightened activity or by the high prevalence of MCT1 and/or MCT4, such as cancer or type II diabetes.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: June 25, 2019
    Assignee: The Scripps Research Institute
    Inventors: Thomas D. Bannister, William R. Roush, Jun Yong Choi, Reji Nair, Andy S. Tsai, Jitendra K. Mishra, John L. Cleveland
  • HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS
    Publication number: 20180002343
    Abstract: The invention provides compounds that inhibit monocarboxylate transporters, such as MCT1 and MCT4. Compounds of the invention can be used for treatment of a condition in a patient, wherein the condition is characterized by the heightened activity or by the high prevalence of MCT1 and/or MCT4, such as cancer or type II diabetes.
    Type: Application
    Filed: January 22, 2016
    Publication date: January 4, 2018
    Inventors: Thomas D. Bannister, William R. Roush, Jun Yong Choi, Reji Nair, Andy S. Tsai, Jitendra K. Mishra, John L. Cleveland
  • Register-transfer level (RTL) design checking for exploring simulation and/or synthesis mismatches and ambiguous language semantics using categorization
    Patent number: 8769454
    Abstract: The present disclosure teaches a system and method for register-transfer level (RTL) design checking for exploring mismatches and ambiguous language semantics that occur during the simulation and synthesis phases of the circuit design. In particular, the present disclosure utilizes identified patterns of design violations that occur as a result of these mismatches to create rule objects. The rule objects are then used to identify circuit design violations relating to mismatches between designer intent and ambiguous language. The rule objects are also categorized into different categories so as aid in the analysis of design rule violations and to identify the major impacts to the design qualities and to provide a confidence level of the overall design quality.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: July 1, 2014
    Assignee: Cadence Design Systems, Inc.
    Inventors: Andy S. Tsay, Kuei Ju Yang, Shih-Chieh Wu